Calcified Tissue International

, Volume 37, Issue 2, pp 126–133 | Cite as

Role of carbonic anhydrase in bone: Partial inhibition of disuse atrophy of bone by parenteral acetazolamide

  • Alexander D. Kenny
Laboratory Investigations


Carbonic anhydrase inhibitor acetazolamide blocks the hypercalcemic response to parathyroid hormone (PTH) and to dibutyrul 3′,5′-cyclic AMP in the nephrectomized-parathyroidectomized rat. In addition, we have reported that acetazolamide, when incorporated in the diet, partially prevents denervation-induced bone loss in a rat model of disuse osteoporosis. The present study compares the effectiveness of orally and subcutaneously administered acetazolamide in preventing denervation-induced bone loss in the rat model. The rats were treated with acetazolamide either orally, by incorporation in the diet of concentrations of 0.2, 0.5, or 1.5% for 15 days, or parenterally by two different subcutaneous methods of administration. The latter included either injection twice daily for 15 days or continuous infusion for 8 days using an osmotic minipump. It was found that parenteral administration was as effective in partially preventing denervation-induced bone mass changes as oral administration. In addition, protection by the parenteral route could be accomplished with much smaller daily doses; continuous infusion required the least daily dose. Approximately 50% protection was observed to occur with daily doses of 1,094, 129, and 8 mg/kg body weight for the oral, subcutaneous injection, and subcutaneous infusion routes respectively. These findings are consistent with our concept that carbonic anhydrase plays a significant role in bone metabolism.

Key words

Acetazolamide Denervation-induced bone loss Oral ingestion Subcutaneous injection Continuous subcutaneous infusion 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Waite LC, Kenny AD (1970) Acetazolamide and calcium metabolism in the rat. In: Taylor S, Foster GV (eds) Calcitonin 1969. William Heinemann Medical Books Ltd, London, p 442Google Scholar
  2. 2.
    Waite LC, Volkert WA, Kenny AD (1970) Inhibition of bone resorption by acetazolamide in the rat. Endocrinology 87:1129–1139PubMedGoogle Scholar
  3. 3.
    Conaway HH, Waite LC, Kenny AD (1973) Immobilization and bone mass in rats: effects of parathyroidectomy and acetazolamide. Calcif tissue Res 11:323–330PubMedCrossRefGoogle Scholar
  4. 4.
    Simasaki M, Yagi T (1960) Histochemistry of carbonic anhydrase with special reference to the osteoclast. Dent Bull Osaka Univ 1:89–98Google Scholar
  5. 5.
    Minkin C, Jenning JM (1972) Carbonic anhydrase and bone remodeling: sulfonamide inhibition of bone resorption in organ culture. Science 176:1031–1033PubMedCrossRefGoogle Scholar
  6. 6.
    Mahgoub A, Stern PH (1974) Carbon dioxide and the effect of parathyroid hormone on bone in vitro. Am J Physiol 226:1272–1275PubMedGoogle Scholar
  7. 7.
    Pierce WM, Waite LC (1981) Acetazolamide inhibition of bone resorption: lack of effect of phosphate release from bone in vitro. Horm Metab Res 13:591–592PubMedGoogle Scholar
  8. 8.
    Hall GE, Kenny AD (1983) Parathyroid hormone increases carbonic anhydrase activity in cultured mouse calvaria. Calcif Tissue Int 35:682Google Scholar
  9. 9.
    Waite LC (1972) Carbonic anhydrase inhibitors, parathyroid hormone and calcium metabolism. Endocrinology 91:1160–1165PubMedGoogle Scholar
  10. 10.
    Lineberry MD, Waite LC (1979) Acidosis inhibits the hypocalcemic effect of acetazolamide. J Pharmacol Exp Ther 211:452–455PubMedGoogle Scholar
  11. 11.
    Pierce WM Jr, Lineberry MD, Waite LC (1982) Effect of sulfonamides on the hypercalcemic response to vitamin D. Horm Metab Res 14:670–673PubMedCrossRefGoogle Scholar
  12. 12.
    Hall GE, Kenny AD (1985) Role of carbonic anhydrase in bone resorption induced by 1,25-dihydroxyvitamin D3 in vitro. Calcif Tissue Int 37:134–142PubMedGoogle Scholar
  13. 13.
    Kenny AD (1978) Protective effect of parenteral acetazolamide in a rat model of disuse atrophy of bone. Pharmacologist 20:152Google Scholar
  14. 14.
    Kenny AD, Toepel W, Schour I (1958) Calcium and phosphorus metabolism in theia rat. J Dent Res 37:432–443PubMedGoogle Scholar
  15. 15.
    Snedecor GW (1956) Statistical methods, Iowa State College Press, AmesGoogle Scholar
  16. 16.
    Kenny AD (1972) Effects of dietary acetazolamide on plasma electrolytes, bone mass, and renal mineral contents in rats. Proc Soc Exp Biol Med 140:135–139PubMedGoogle Scholar
  17. 17.
    Hall GE, Kenny AD (1984) The role of carbonic anhydrase in dibutyryl cyclic AMP-induced bone resorption. Abstracts of the 40th Southwest Regional American Chemical Society Meeting, p 40Google Scholar
  18. 18.
    Gunasekaran S, Hall GE, Kenny AD (1984) Effect of forskolin on neonatal mouse bone metabolismin vitro. Abstracts of the 40th Southwest Regional American Chemical Society Meeting, p 40Google Scholar
  19. 19.
    Frost HM (1983) Pharmacology and the osteoporoses: a field in flux. Meth Find Exp Clin Pharmacol 5:5–16Google Scholar
  20. 20.
    Kenny AD, Yee JA, Lutherer LO (1979) Inhibition of disuse atrophy of bone in rats by continuous subcutaneous infusion of acetazolamide. Calcif Tissue Int 28:157Google Scholar
  21. 21.
    Kenny AD (1962) Glycogenolytic action of epinephrine on mouse parietal bones. Endocrinology 71:901–905PubMedCrossRefGoogle Scholar
  22. 22.
    Kenny AD (1964) Effect of catecholamines on serum calcium and phosphorus levels in intact and parathyroidectomized rats. Naunyn-Schmiedebergs Arch Exp Path Pharmak 248:144–152CrossRefGoogle Scholar
  23. 23.
    Morey ER, Kenny AD (1964) Effect of catecholamines on urinary calcium and phosphorus in intact and parathyroidectomized rats. Endocrinology 75:78–85PubMedGoogle Scholar
  24. 24.
    Sly WS, Hewett-Emmett D, Whyte MP, Yu Y-SL, Tashian RE (1983) Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80:2752–2756PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • Alexander D. Kenny
    • 1
  1. 1.Department of PharmacologyTexas Tech University Health Sciences CenterLubbock

Personalised recommendations